Philippe Beutels1, Mark Jit. 1. Centre for Health Economics Research and Modeling Infectious Diseases, University of Antwerp, Antwerp 2610, Belgium. philippe.beutels@ua.ac.be
Abstract
BACKGROUND: This commentary discusses key issues for health economic evaluation and modelling, applied to human papillomavirus (HPV) vaccine programs. METHODS: We outline some of the specific features of HPV disease and vaccination, and associated policy questions in light of a literature search for economic evaluations on HPV vaccination. RESULTS: We observe that some policy questions could not be reliably addressed by many of the 43 published economic evaluations we found. Despite this, policy making on universal HPV vaccination followed shortly after vaccine licensure in many developed countries, so the role economic evaluation played in informing these decisions (pre-dating 2008) seems to have been fairly limited. For more recent decisions, however, economic evaluation is likely to have been used more widely and more intensively. CONCLUSIONS: We expect future cost-effectiveness analyses to be more instrumental in policy making regarding vaccines covering more HPV types, therapeutic HPV vaccines, and novel diagnostic tests for biomarkers of HPV infection and disease integrated with cervical screening programs.
BACKGROUND: This commentary discusses key issues for health economic evaluation and modelling, applied to human papillomavirus (HPV) vaccine programs. METHODS: We outline some of the specific features of HPV disease and vaccination, and associated policy questions in light of a literature search for economic evaluations on HPV vaccination. RESULTS: We observe that some policy questions could not be reliably addressed by many of the 43 published economic evaluations we found. Despite this, policy making on universal HPV vaccination followed shortly after vaccine licensure in many developed countries, so the role economic evaluation played in informing these decisions (pre-dating 2008) seems to have been fairly limited. For more recent decisions, however, economic evaluation is likely to have been used more widely and more intensively. CONCLUSIONS: We expect future cost-effectiveness analyses to be more instrumental in policy making regarding vaccines covering more HPV types, therapeutic HPV vaccines, and novel diagnostic tests for biomarkers of HPV infection and disease integrated with cervical screening programs.
Authors: E Lynne Conway; K Chip Farmer; William J Lynch; Guy L Rees; Gerard Wain; Jane Adams Journal: Sex Transm Infect Date: 2012-05-29 Impact factor: 3.519
Authors: Mark Jit; Nadia Demarteau; Elamin Elbasha; Gary Ginsberg; Jane Kim; Naiyana Praditsitthikorn; Edina Sinanovic; Raymond Hutubessy Journal: BMC Med Date: 2011-05-12 Impact factor: 8.775